Search

Electrocatalysis can synthesize kinds of valuable chemicals and plays vital role in developing clean and renewable energy storage and conversion devices. In the traditional electrocatalytic systems, researchers try to synthesize one type of valuable chemical at cathode or anode independently. Recently, electrocatalytic bipolar synthesis of valuable chemicals at both cathode and anode simultaneously becomes popular and attracts much attention. In this minireview, we summarize the latest processes on innovative strategies for electrocatalytic bipolar synthesis of various chemicals. We will discuss the findings according to the categories of the products, including bipolar hydrogen production, bipolar formate production and bipolar hydrogenation. And the associated catalysts optimization, reaction mechanism, and design principles are well introduced. Moreover, the challenges and prospects are highlighted for future developments. This review is timely and will guide others pay more attention to this novel electrocatalytic bipolar synthesis systems. [ABSTRACT FROM AUTHOR]

Background: The relationship between Protein Convertase Subtilisin Kexin Type 9 inhibitor (PCSK9i) and psychiatric adverse events (AEs) remains unclear due to the limitations of clinical trials. In this study, PCSK9i‐related psychiatric AEs were realistically observed and systematically summarized in the real world by data mining the FDA AE Reporting System (FAERS). Method: Total AEs between the third quarter of 2015 and the first quarter of 2023 were obtained from FAERS. Psychiatric AEs were identified using disproportionality analysis and clinical prioritization of signals using a rating scale, followed by univariate logistic regression to explore factors influencing psychiatric AEs. Results: Psychiatric AEs accounted for 6.7% of the total number of PCSK9i reports. Eighteen psychiatric AEs were defined as PCSK9i‐related psychiatric adverse events (ppAEs) (lower 95% CI of both ROR >1 and IC025 > 0). The median age of ppAE reports was 68 years, and female patients accounted for 22.67% of reports, including 41.40% of reports with a serious outcome. Eleven (61.11%) and seven (38.89%) ppAEs were classified as weak and moderate clinical priority, respectively. The median time to onset of ppAEs was 149 and 196 days after treatment with evolocumab and alirocumab, respectively. Patients weighing ≥80 kg were 1.59 times more likely to experience ppAEs. Conclusion: The results of this study facilitate the prioritization of psychiatric AE signals by healthcare professionals with the goal of mitigating the risk of PCSK9i‐related psychiatric AEs. However, as an exploratory study, our findings need to be confirmed in large‐scale prospective studies. [ABSTRACT FROM AUTHOR]

Geospatial data, especially remote sensing (RS) data, are of significant importance for public services and production activities. Expertise is critical in processing raw data, generating geospatial information, and acquiring domain knowledge and other remote sensing applications. However, existing geospatial service platforms are more oriented towards the professional users in the implementation process and final application. Building appropriate geographic applications for non-professionals remains a challenge. In this study, a geospatial data service architecture is designed that links desktop geographic information system (GIS) software and cloud-based platforms to construct an efficient user collaboration platform. Based on the scalability of the platform, four web apps with different themes are developed. Data in the fields of ecology, oceanography, and geology are uploaded to the platform by the users. In this pilot phase, the gap between non-specialized users and experts is successfully bridged, demonstrating the platform's powerful interactivity and visualization. The paper finally evaluates the capability of building spatial data infrastructures (SDI) based on GeoNode and discusses the current limitations. The support for three-dimensional data, the improvement of metadata creation and management, and the fostering of an open geo-community are the next steps. [ABSTRACT FROM AUTHOR]

Hydrogen energy has a significant and incredible impact on emerging technologies. However, the eco-friendly and clean production of hydrogen energy is under examination and challenging. Water splitting has been considered a sparkling and substantial resource for hydrogen energy, which is strongly dependent on the efficiency of the electrocatalysts. Owing to low cost, rich surface chemistry, greater electrocatalytic active sites, electrical conductivity and weak Se–H strength, metal selenides have originated the efficient electrocatalysts among the chalcogenides family. Several strategies have been adopted to enhance their electrocatalytic characteristics for hydrogen evolution reactions, either in the form of single or multi-metals selenides or post-transition elements doped metal selenides. Herein, fundamentals, synthesis methodologies, and the detailed electrocatalytic activities of the metal selenides have been comprehensively presented. The existing drawbacks and market values have also been concisely summarized for fresh readers and researchers to describe metal selenide electrocatalysts for hydrogen evolution reaction. • Hydrogen energy has a remarkable significance for recent technologies. • Synthesis strategies have been discussed. • Different strategies for Single metal selenides have been discussed. • Multi-metals-based metal selenides have been summarized. • Post-transition elements doped metal selenides have been summarized. [ABSTRACT FROM AUTHOR]

Experimental observations revealed that the amyloid-β 42 oligomer (AβO) can directly bind to the LilrB2 D1D2(LDD) receptor with nanomolar-affinity, leading to changes in synaptic plasticity and cognitive deficits. However, the dependence of neurotoxicity on the morphology, size, and aggregation stage (SP1, SP2) of AβO, as well as the specific molecular mechanism of AβO–LDD interaction, remain uncertain. To address these uncertainties, we investigated the interaction between the LDD neuroreceptor and AβO with different Aβ42 species (nontoxic species, toxic species, and protofibril) and sizes. Our results showed that the LDD selectively binds AβO species rather than the Aβ42 monomer, accommodating various Aβ42 dimers and trimers as well as SP2 AβO, in a specific pose in the pocket of the LDD receptor (region I). Additionally, protofibrils with exposed β1/β2 regions can also bind to region I of the LDD receptor, as observed experimentally (Cao, et al., Nat. Chem., 2018, 10, 1213; and Aim et al., Nat. Commun., 2021, 12, 3451). More extensively, we identified two additional regions of the LDD receptor, regions II and III, suitable for binding to larger AβO species at the SP1 with different molecular weights and conformations, accounting for the stronger binding strength obtained experimentally. We suggest that the two regions are more competitive than region I in causing toxicity by AβO binding. The detailed and systematic characterization for the complexes generated between the LDD receptor and various AβO species, including the protofibril, offers deep insight into the dependence of neurotoxicity on the AβO size and conformation at the molecular level, and provides novel and specific targets for drug design of Alzheimer's disease. [ABSTRACT FROM AUTHOR]

Fibrous aggregates of beta-amyloid (Aβ) is a hallmark of Alzheimer's disease (AD). Several major strategies of drugs or inhibitors, including neutral molecules, positive or negative ions, and dual-inhibitor, are used to inhibit the misfolding or aggregation of Aβ42, among which a kind of dual-inhibitor composed of a pair of positive and negative ions is emerging as the most powerful candidate. This knowledge lacks the origin of the strong inhibitory effect and synergy mechanisms blocking the development and application of such inhibitors. To this end, we employed 1 : 1 ionic pairs (IP) of oppositely charged benzothiazole molecules (+)BAM1-EG6 (Pos) and (−)BAM1-EG6 (Neg) as well as equimolar neutral BAM1-EG6 (Neu) counterpart at two pH conditions (5.5 and 7.0) to bind Aβ42 targets, Aβ42 monomer (AβM), soluble pentamer (AβP), and pentameric protofibril (AβF) models, respectively, corresponding to the products of three toxic Aβ42 development pathways, lag, exponential and fibrillation phases. Simulated results illustrated the details of the inhibitory mechanisms of IP and Neu for the AβY (Y = M, P, or F) in the three different phases, characterizing the roles of Pos and Neg of IP as well as their charged, hydrophobic groups and linker playing in the synergistic interaction, and elucidated a previously unknown molecular mechanism governing the IP-Aβ42 interaction. Most importantly, we first revealed the origin of the stronger binding of IP inhibitors to Aβ42 than that of the equimolar neutral counterparts, observing a perplexing phenomenon that the physiological condition (pH = 7.0) than the acidic one (pH = 5.5) is more favorable to the enhancement of IP binding, and finally disclosed that solvation is responsible to the enhancement because at pH 7.0, AβP and AβF act as anionic membranes, where solvation plays a critical role in the chemoelectromechanics. The result not only provides a new dimension in dual-inhibitor/drug design and development but also a new perspective for uncovering charged protein disaggregation under IP-like inhibitors. [ABSTRACT FROM AUTHOR]